Akram Ahangarpour1, Fatemeh Ramezani Ali Akbari2, Hadi Fathi Moghadam3. 1. Health Research Institute, Diabetes Research Center, Department of Physiology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 61335-189, Iran. 2. School of medicine, Department of Physiology and Member of Student Research Committee of Ahvaz Jundishapur University of Medical Science, Ahvaz 61335-189, Iran. 3. Department of Physiology, Physiology Research Center of Ahvaz Jundishapur University of Medical Sciences, Ahvaz 61335-189, Iran.
Abstract
BACKGROUND: Both C-peptide and nicotinamide are known to reduce blood glucose in type 1 diabetes. In the present study, the effects of C-peptide alone or in combination with nicotinamide on glucose and insulin levels in streptozotocin-nicotinamide-induced type 2 diabetic mice. METHODS: The study used 70 adult male NMARI mice, weighing 25-35 g, divided into seven groups: control; type 1 diabetic; type 2 diabetic; type 2 diabetic + C-peptide; type 2 diabetic + nicotinamide; type 2 diabetic + nicotinamide and C-peptide; type 2 diabetic + glyburide. Type 2 diabetes was induced with ip injection of streptozotocin-nicotinamide. Twenty eight days after the onset of diabetes, treatment with C-peptide, nicotinamide, nicotinamide + C-peptide, or glyburide were initiated. Glucose and insulin levels were evaluated. One-way ANOVA and Least Significant Difference (LSD) tests were used to test for significance. RESULTS: Blood glucose significantly increased (P < 0.001) in all diabetic mice compared with control mice. Insulin resistance and blood glucose levels were significantly reduced (P < 0.05) in C-peptide and nicotinamide + C-peptide mice compared with type 2 diabetic mice. CONCLUSION: The present study supports the anti-diabetic effects of C-peptide, nicotinamide + C-peptide, and suggests that one of the anti-diabetic mechanisms of these compounds is mediated through the reduction of insulin resistance.
BACKGROUND: Both C-peptide and nicotinamide are known to reduce blood glucose in type 1 diabetes. In the present study, the effects of C-peptide alone or in combination with nicotinamide on glucose and insulin levels in streptozotocin-nicotinamide-induced type 2 diabeticmice. METHODS: The study used 70 adult male NMARI mice, weighing 25-35 g, divided into seven groups: control; type 1 diabetic; type 2 diabetic; type 2 diabetic + C-peptide; type 2 diabetic + nicotinamide; type 2 diabetic + nicotinamide and C-peptide; type 2 diabetic + glyburide. Type 2 diabetes was induced with ip injection of streptozotocin-nicotinamide. Twenty eight days after the onset of diabetes, treatment with C-peptide, nicotinamide, nicotinamide + C-peptide, or glyburide were initiated. Glucose and insulin levels were evaluated. One-way ANOVA and Least Significant Difference (LSD) tests were used to test for significance. RESULTS:Blood glucose significantly increased (P < 0.001) in all diabeticmice compared with control mice. Insulin resistance and blood glucose levels were significantly reduced (P < 0.05) in C-peptide and nicotinamide + C-peptide mice compared with type 2 diabeticmice. CONCLUSION: The present study supports the anti-diabetic effects of C-peptide, nicotinamide + C-peptide, and suggests that one of the anti-diabetic mechanisms of these compounds is mediated through the reduction of insulin resistance.
Entities:
Keywords:
C-peptide; diabetes type 2; insulin resistance; mice; nicotinamide
Authors: Joseph Grimsby; Ramakanth Sarabu; Wendy L Corbett; Nancy-Ellen Haynes; Fred T Bizzarro; John W Coffey; Kevin R Guertin; Darryl W Hilliard; Robert F Kester; Paige E Mahaney; Linda Marcus; Lida Qi; Cheryl L Spence; John Tengi; Mark A Magnuson; Chang An Chu; Mark T Dvorozniak; Franz M Matschinsky; Joseph F Grippo Journal: Science Date: 2003-07-18 Impact factor: 47.728